Literature DB >> 10764154

Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene.

W J Rombouts1, I Blokland, B Löwenberg, R E Ploemacher.   

Abstract

Internal tandem duplications of the FIt3 gene (FIt3/ITDs) are present in about 18% of all AML cases and are therefore one of the most frequent somatic gene mutations in AML. Little is known about the role of FIt3/ITDs in leukemogenesis or their clinical relevance. In this study we compared 18 samples with FIt3/ITDs and 63 AML samples without these mutations with respect to clinical prognosis, cytokine responsiveness, progenitor cell content and repopulation in the NOD/SCID mouse. We found that in patients with a mutation CR rates are reduced (P=0.03) and relapse rates are increased (P=0.01), indicating the prognostic importance of FIt3/ITDs. This is also emphasized by the finding that in patients under the age of 60 years, as well as in older patients the event-free survival was more unfavorable for the mutant patients (P=0.003 and P=0.03, respectively). At diagnosis FIt3/ITD and non-mutant AML bone marrow samples did not differ in their progenitor/stem cell frequencies. Cobblestone area forming cell (CAFC) subsets showed a similar frequency distribution in mutant and non-mutant samples. In 7-day liquid cultures, FIt3/ITD samples showed a reduced growth in response to a variety of myeloid growth factors. In contrast, FIt3/ITD samples displayed a higher ability to engraft the NOD/SCID bone marrow with leukemic cells. Together these data show that the FIt3/ITD represents an important diagnostic marker for patient prognosis, and that the presence of these mutations is associated with altered proliferative ability of progenitors in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10764154     DOI: 10.1038/sj.leu.2401731

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  58 in total

Review 1.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Authors:  Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Irwin D Bernstein
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

Review 2.  Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.

Authors:  Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

Review 3.  Clinical significance of FLT3 in leukemia.

Authors:  Hitoshi Kiyoi; Masamitsu Yanada; Kazutaka Ozekia
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

4.  Mutation of FLT3 gene in acute myeloid leukemia with normal cytogenetics and its association with clinical and immunophenotypic features.

Authors:  Pradeep S Chauhan; Bharat Bhushan; Ashwani K Mishra; Laishram C Singh; Sumita Saluja; Saurabh Verma; Dipendra K Gupta; Vishakha Mittal; Sumita Chaudhry; Sujala Kapur
Journal:  Med Oncol       Date:  2010-03-31       Impact factor: 3.064

5.  Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation.

Authors:  Christina D Drenberg; Daelynn R Buelow; Stanley B Pounds; Yong-Dong Wang; David Finkelstein; Richard J Rahija; Sheila A Shurtleff; Jeffrey E Rubnitz; Hiroto Inaba; Tanja A Gruber; Jeffery M Klco; Sharyn D Baker
Journal:  Leuk Lymphoma       Date:  2016-06-01

6.  The influence of mutational status and biological characteristics of acute myeloid leukemia on xenotransplantation outcomes in NOD SCID gamma mice.

Authors:  Martin Culen; Zdenka Kosarova; Ivana Jeziskova; Adam Folta; Jana Chovancova; Tomas Loja; Nikola Tom; Vojtech Bystry; Veronika Janeckova; Dana Dvorakova; Jiri Mayer; Zdenek Racil
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-02       Impact factor: 4.553

Review 7.  Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

Authors:  Keith Pratz; Mark Levis
Journal:  Leuk Lymphoma       Date:  2008-05

8.  Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.

Authors:  Ellen Weisberg; Johannes Roesel; Guido Bold; Pascal Furet; Jingrui Jiang; Jan Cools; Renee D Wright; Erik Nelson; Rosemary Barrett; Arghya Ray; Daisy Moreno; Elizabeth Hall-Meyers; Richard Stone; Ilene Galinsky; Edward Fox; Gary Gilliland; John F Daley; Suzan Lazo-Kallanian; Andrew L Kung; James D Griffin
Journal:  Blood       Date:  2008-09-26       Impact factor: 22.113

9.  A robust xenotransplantation model for acute myeloid leukemia.

Authors:  P V Sanchez; R L Perry; J E Sarry; A E Perl; K Murphy; C R Swider; A Bagg; J K Choi; J A Biegel; G Danet-Desnoyers; M Carroll
Journal:  Leukemia       Date:  2009-07-23       Impact factor: 11.528

10.  Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia.

Authors:  Mohamed Elmeliegy; Jason Den Haese; Chetasi Talati; Meir Wetzler; William J Jusko
Journal:  Cancer Chemother Pharmacol       Date:  2020-08-03       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.